Literature DB >> 27530055

The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy.

Maria Ester Bernardo1, Alessandro Aiuti1,2.   

Abstract

Gene therapy (GT) approaches based on autologous hematopoietic stem cells (HSC) corrected ex vivo have shown therapeutic benefit in a number of inherited disorders. GT bares the advantage of allowing each patient to be her/his own donor while reducing the risks of immune-mediated complications as compared with allogeneic hematopoietic stem-cell transplantation (HSCT). In order to achieve stable engraftment of HSC, patients undergoing transplantation of allogeneic or autologous HSC receive a chemotherapy- and/or radiotherapy-based preparation. With regard to HSC-GT for inherited genetic disorders, the ideal conditioning regimen should aim to contain toxicity by reducing the dosage and/or the number of chemotherapeutic agents administered, in comparison to fully myeloablative preparations employed in conventional allogeneic HSCT. To meet this aim, a profound knowledge of the disease-specific biological background and of the therapeutic transgene levels, as well as of the key principles of transplantation, are required. While low-dose conditioning is sufficient to create a mixed chimerism when gene-corrected cells are endowed with a natural selective advantage, such as in the case of immune deficiencies, myeloablative doses are necessary when high levels of engraftment are required in disease such as lysosomal storage disorders and beta thalassemia. Therefore, the intensity and type of conditioning regimen administered to patients undergoing HSC-GT should be tailored to reach a minimal efficacious therapeutic target level while sparing toxicity. Novel strategies based on monoclonal antibodies selectively depleting blood cells and associated with limited extramedullary toxicity might be successfully employed in the context of HSC-GT in the near future. This review focuses on the role of the conditioning regimen in HSC-GT, and in particular, it highlights the importance of modulating the preparative chemotherapy based on disease biology and transgene expression in order to optimize outcome.

Entities:  

Mesh:

Year:  2016        PMID: 27530055     DOI: 10.1089/hum.2016.103

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  17 in total

Review 1.  In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions.

Authors:  Serena Scala; Alessandro Aiuti
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Gene therapy using haematopoietic stem and progenitor cells.

Authors:  Giuliana Ferrari; Adrian J Thrasher; Alessandro Aiuti
Journal:  Nat Rev Genet       Date:  2020-12-10       Impact factor: 53.242

3.  Induction of TGF-β by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow Is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350.

Authors:  Michael W Epperly; Byung-Han Rhieu; Darcy Franicola; Tracy Dixon; Shaonan Cao; Xichen Zhang; Donna Shields; Hong Wang; Peter Wipf; Joel S Greenberger
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

Review 4.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

Review 5.  The transformative potential of HSC gene therapy as a genetic medicine.

Authors:  Pervinder Sagoo; H Bobby Gaspar
Journal:  Gene Ther       Date:  2021-05-26       Impact factor: 5.250

Review 6.  Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point of View.

Authors:  Marina Cavazzana; Jean-Antoine Ribeil; Chantal Lagresle-Peyrou; Isabelle André-Schmutz
Journal:  Stem Cells Dev       Date:  2016-10-16       Impact factor: 3.272

7.  Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I.

Authors:  Isabella Azario; Alice Pievani; Federica Del Priore; Laura Antolini; Ludovica Santi; Alessandro Corsi; Lucia Cardinale; Kazuki Sawamoto; Francyne Kubaski; Bernhard Gentner; Maria Ester Bernardo; Maria Grazia Valsecchi; Mara Riminucci; Shunji Tomatsu; Alessandro Aiuti; Andrea Biondi; Marta Serafini
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

Review 8.  Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Deficiency: From Pathogenesis to Emerging Therapeutic Options.

Authors:  Rana Yadak; Peter Sillevis Smitt; Marike W van Gisbergen; Niek P van Til; Irenaeus F M de Coo
Journal:  Front Cell Neurosci       Date:  2017-02-15       Impact factor: 5.505

9.  Innovations Needed for Effective Implementation of Ex Vivo Gene Therapies.

Authors:  Marina Cavazzana
Journal:  Front Med (Lausanne)       Date:  2017-03-24

Review 10.  Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.

Authors:  Rachele Penati; Francesca Fumagalli; Valeria Calbi; Maria Ester Bernardo; Alessandro Aiuti
Journal:  J Inherit Metab Dis       Date:  2017-05-30       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.